Inhibikase Therapeutics Inc Ordinary Shares IKT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $2.34
- Day Range
- $2.34–2.43
- 52-Week Range
- $1.33–2.61
- Bid/Ask
- $2.39 / $2.40
- Shares Outstanding
- 139.54M
- Market Cap
- $333.49M
- Volume/Avg
- 481,476 / 743,070
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 35
- Website
- https://www.inhibikase.com
Valuation
|
Metric
|
IKT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.01 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
IKT
Financial Strength
|
Metric
|
IKT
|
|---|---|
Quick Ratio | 15.50 |
Current Ratio | 15.82 |
Interest Coverage | — |
Quick Ratio
IKT
Profitability
|
Metric
|
IKT
|
|---|---|
Return on Assets (Normalized) | −29.78% |
Return on Equity (Normalized) | −31.61% |
Return on Invested Capital (Normalized) | −35.32% |
Return on Assets
IKT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#C^xHk | LOCK|q%!Z@ | $131B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|r!d#?S | LOCK|bS^> | $80B | |||
| argenx SE ADR
ARGX
| LOCK|K@Y>T?r | LOCK|?h | $62B | |||
| Moderna Inc
MRNA
| LOCK|C%?^<Y | LOCK|TR | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|lt!p>^% | LOCK|Ltl | $40B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|WBx!!c | LOCK|!?jH# | $33B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|PdGV<t<R | LOCK|?^!G | $26B | |||
| Incyte Corp
INCY
| LOCK|<$#^L#C | LOCK|$Y | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|nLp>^>g | LOCK|@gq | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|w@L%dD | LOCK|ny< | $16B |
United States